Trials / Terminated
TerminatedNCT03346538
Dose Finding Study of MCI-186 in Acute Ischemic Stroke
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 17 (actual)
- Sponsor
- Tanabe Pharma Corporation · Industry
- Sex
- All
- Age
- 20 Years – 85 Years
- Healthy volunteers
- Not accepted
Summary
To investigate the efficacy and safety of MCI-186 (bolus followed by continuous infusion) in acute ischemic stroke patients through a double-blind, parallel-group comparison with the existing MCI-186 dosing regimen (administration twice daily for 14 days) as the control.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Continuous infusion high-dose MCI-186 | intravenous injection |
| DRUG | Continuous infusion low-dose MCI-186 | intravenous injection |
| DRUG | Continuous infusion placebo | intravenous injection |
| DRUG | Approved dosing regimen MCI-186 | intravenous injection |
| DRUG | Approved dosing regimen placebo | intravenous injection |
Timeline
- Start date
- 2017-11-17
- Primary completion
- 2018-05-14
- Completion
- 2018-05-14
- First posted
- 2017-11-17
- Last updated
- 2026-01-08
- Results posted
- 2025-01-09
Locations
45 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT03346538. Inclusion in this directory is not an endorsement.